Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gensulin N is an intermediate-acting recombinant human insulin (NPH/isophane) developed by BIOTON for the management of diabetes mellitus. It is produced using recombinant DNA technology and formulated as a crystalline suspension with protamine and zinc, which delays its absorption from the subcutaneous injection site, resulting in a prolonged duration of action compared to regular soluble insulin. The drug acts as an agonist at the insulin receptor, stimulating glucose uptake in peripheral tissues such as skeletal muscle and adipose tissue, while simultaneously inhibiting hepatic glucose production. It is typically used to provide basal insulin coverage throughout the day or night.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human insulin isophane.